Wells Fargo analyst Cerena Chen lowered the firm’s price target on Amphastar (AMPH) to $35 from $40 and keeps an Overweight rating on the shares. The firm says that continued expectations for 2 launches this year despite recent CRLs is reassuring though it notes sales contribution would be more meaningful in 2026. Good Baqsimi and Primatene growth make Wells less concerned about competitive pressure elsewhere.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMPH:
- Cautious Hold Rating for Amphastar Pharmaceuticals Amid Competitive Pressures and Revenue Challenges
- Amphastar Pharmaceuticals: Neutral Stance Amid Mixed Financial Outlook and Pipeline Uncertainty
- Amphastar Pharmaceuticals Reports Q1 2025 Earnings
- Amphastar Pharmaceuticals Inc (AMPH) Q1 Earnings Cheat Sheet
- Amphastar price target lowered to $31 from $36 at BofA